title: Plasma pentraxin 3 levels are associated with carotid IMT in type 1 diabetic patients.
abstract: OBJECTIVE
  Pentraxin3 (PTX3), a recently discovered inflammatory mediator, is produced abundantly in various cells in atherosclerotic lesions, and therefore, its plasma level could reflect local inflammation at the site of atherosclerotic lesion. The present study evaluated whether plasma PTX3 levels are associated with subclinical atherosclerosis in young subjects with type 1 diabetes.
  
  
  METHODS
  Plasma PTX3 levels, urinary albumin excretion, diabetic retinopathy, and carotid intima-media thickness (IMT) were examined in 78 Japanese type 1 diabetic patients (30 men and 48 women, aged 28.5 ± 5.3 years (±SD), duration of diabetes 19.7 ± 6.5 years).
  
  
  RESULTS
  There was statistically significant association between plasma PTX3 levels and Max-IMT (r=0.363, p=0.001). A stepwise multivariate regression analysis including conventional coronary risk factors as independent variables revealed that plasma PTX3 levels (β=0.389, p<0.001), duration of diabetes (β=0.256, p=0.035), and serum triglyceride levels (β=0.371, p<0.001) were independent determinants of Max-IMT. In addition, plasma PTX3 levels was an independent determinant of urinary albumin excretion, an indicator of diabetic nephropathy (β=0.258, p=0.018). However, there was no significant association between plasma PTX3 levels and diabetic retinopathy.
  
  
  CONCLUSIONS
  Increased levels of plasma PTX3 are associated with accelerated atherosclerotic change and increased albuminuria in young patients with type 1 diabetes.
authors.affiliation: Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan. katakami@medone.med.osaka-u.ac.jp
authors.forename: Naoto
authors.initials: N
authors.lastname: Katakami
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kaneto
authors.forename: Fumie
authors.initials: F
authors.lastname: Sakamoto
authors.forename: Mitsuyoshi
authors.initials: M
authors.lastname: Takahara
authors.forename: Yoko
authors.initials: Y
authors.lastname: Irie
authors.forename: Keiko
authors.initials: K
authors.lastname: Fujisawa
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Miyashita
authors.forename: Tetsuyuki
authors.initials: T
authors.lastname: Yasuda
authors.forename: Taka-aki
authors.initials: TA
authors.lastname: Matsuoka
authors.forename: Kazutomi
authors.initials: K
authors.lastname: Yoshiuchi
authors.forename: Ken'ya
authors.initials: K
authors.lastname: Sakamoto
authors.forename: Akio
authors.initials: A
authors.lastname: Kuroda
authors.forename: Munehide
authors.initials: M
authors.lastname: Matsuhisa
authors.forename: Keisuke
authors.initials: K
authors.lastname: Kosugi
authors.forename: Iichiro
authors.initials: I
authors.lastname: Shimomura
mesh_terms: D000328:Adult; D050197:Atherosclerosis / Q000097:blood / Q000473:pathology; D002097:C-Reactive Protein / Q000378:metabolism*; D002339:Carotid Arteries / Q000473:pathology; D002340:Carotid Artery Diseases / Q000097:blood / Q000473:pathology; D059168:Carotid Intima-Media Thickness; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D000683:Serum Amyloid P-Component / Q000378:metabolism*; D055815:Young Adult; D000099153:Pentraxins
chemical_list: D002097:C-Reactive Protein; D000683:Serum Amyloid P-Component; D000099153:Pentraxins